To investigate patient needs, preferences and priorities for T1DM management, and to assess, from the patient's perspective, the utility, suitability, and viability of GLP‐1 RAs as an adjunct to insulin therapy in T1DM. The gene discussed is INS; the disease is type 1 diabetes mellitus.